secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-01-31T23:59:59+00:00
Accession:  0001493152-22-002608
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace terminates rights offering due to adverse CMS policy change for thyroid tests
--------------------------------------------------------------------------------

- Terminated rights offering and standby purchase agreement with 3K Limited Partnership effective January 28, 2022.
- CMS issued new billing policy: no longer reimburses ThyGeNEXT and ThyraMIR tests when billed together for same beneficiary on same date.
- Company evaluating potential financial impact and preparing an appeal; seeking alternative financing sources.
- CEO stated rights offering termination driven by likely adverse impact of CMS policy change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222002608/0001493152-22-002608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222002608/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-002608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer